Journal of Cancer Biology and Clinical Oncology

Intestinal Microbiota Associated With The Efficacy Of Immune Checkpoint Inhibitor Therapy With Anti-Pd-1/ Pd-L1 Antibody

Author(s): Tadashi Ohara, Yasuyuki Taki

We explained about reports of fecal bacteria that could be biomarkers related to the efficacy of immune checkpoint inhibitor therapy with anti-PD-1/PD-L1 antibody against melanoma, non-small cell lung carcinoma (NSCLC), urothelial and renal cell carcinoma (UTC/RCC). It has been reported that the proportion of bacteria in the family Ruminococcaseae and Faecalibacterium affects the efficacy of immune checkpoint inhibitor therapy as biomarkers against melanoma, and Akkermansia muchiniphila as a biomarker against NSCLC and UTC/ RCC. However, it is unlikely that these intestinal bacteria can be applied to all carcinomas, and the mechanism of antitumor effects in these bacteria has not yet been fully elucidated.

Download pdf

Will be updated soon

Mission and Vision Membership Withdrawal Policy Submit Paper Publication ethics
Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License © 2018